Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial

The Lancet. Diabetes & Endocrinology
Weiping JiaJun Yang

Abstract

Unlike in western countries, premixed insulin is widely used as the starter insulin in Asian patients instead of basal insulin. The use of basal-bolus therapy as an intensification regimen is not common in Asia despite poor glycaemic control after starting insulin therapy. An alternative insulin intensification regimen with a similar efficacy and safety profile to basal-bolus therapy, but of higher convenience, is urgently needed. The efficacy and safety of insulin lispro mix thrice-daily was compared with basal-bolus therapy in Asian patients with type 2 diabetes who were insufficiently controlled on twice-daily premixed insulin. This open-label, randomised, active comparator-controlled, parallel-group trial was done at 24 centres in China, Taiwan, and South Korea. Patients with type 2 diabetes who were inadequately controlled on twice-daily premixed insulin were randomly assigned (1:1) to receive either insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner) or basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily) for 24 weeks. Randomisation was done by a computer-generated random sequence and was stratified by country or region and baseline HbA1c. Treatment assig...Continue Reading

References

Mar 31, 1998·Journal of Pharmaceutical Sciences·M R DeFelippisB H Frank
Sep 27, 2002·The Korean Journal of Internal Medicine·Sang Guk KimMin Young Chung
Oct 31, 2002·Clinical Pharmacokinetics·Paris Roach, James R Woodworth
Feb 13, 2009·Current Medical Research and Opinion·Changyu PanHui Tian
Jan 28, 2010·Diabetes Care·Mark PeyrotLuther B Travis
Mar 26, 2010·The New England Journal of Medicine·Wenying YangUNKNOWN China National Diabetes and Metabolic Disorders Study Group
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Yu XuUNKNOWN 2010 China Noncommunicable Disease Surveillance Group

❮ Previous
Next ❯

Citations

Feb 4, 2016·Journal of Diabetes Research·Feng-Fei LiJian-Hua Ma
Sep 10, 2015·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay Kalra, Yashdeep Gupta
Feb 15, 2013·Journal of the Science of Food and Agriculture·Zhenzhu XuJunye Zhao
Mar 24, 2016·Endocrine·Maria Ida MaiorinoDario Giugliano
Sep 24, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Michelle DownieJencia Wong
Dec 9, 2016·Journal of Diabetes Investigation·Wayne H-H SheuThomas Lew
Apr 15, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Riccardo CandidoEster Romoli
Oct 27, 2017·Current Medical Research and Opinion·Ignacio CongetDavid M Kendall
Jul 2, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Li Xin ShiJia Ning Hou
Apr 26, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Takahisa HiroseJacek Kiljański
Apr 8, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Ting HongYan Bi
Aug 24, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Feng-Fei LiJian-Hua Ma
Nov 20, 2016·Diabetes Technology & Therapeutics·Abraham Edgar Gracia-RamosJosé Leopoldo Aguilar-Faisal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.